APP
IONS icon

Alpha Paradigm Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Alpha Paradigm Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$202K Buy
+5,335
New +$224K 0.08% 310
2021
Q1 		– Sell
-5,348
Closed -$302K – 569
2020
Q4 		$302K Buy
+5,348
New +$267K 0.1% 219

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Alpha Paradigm Partners's IONS Position: Q4 2022 in Review

Alpha Paradigm Partners opened a new position in Ionis Pharmaceuticals (IONS) in Q4 2022: 5,335 shares worth $202K. The stake represents 0.08% of the portfolio and ranks #310 among its holdings. This is a return to the name: Alpha Paradigm Partners previously reported a position in IONS as recently as Q4 2020.

Alpha Paradigm Partners first reported a position in IONS in Q4 2020 and has held it in 2 quarters since. The position peaked at $302K in Q4 2020. 338 funds tracked by Wall St. Rank hold IONS as of Q4 2022.

  • Alpha Paradigm Partners held 5,335 shares of Ionis Pharmaceuticals worth $202K as of Q4 2022.
  • Ionis Pharmaceuticals was a new Alpha Paradigm Partners position in Q4 2022.
  • Ionis Pharmaceuticals made up 0.08% of Alpha Paradigm Partners's portfolio in Q4 2022, its #310 holding.
  • Alpha Paradigm Partners first reported a position in Ionis Pharmaceuticals in Q4 2020 and has held it in 2 quarters since.
  • Alpha Paradigm Partners's Ionis Pharmaceuticals position peaked at $302K in Q4 2020.
  • 338 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.